Research Article

Serotonin-Exacerbated DSS-Induced Colitis Is Associated with Increase in MMP-3 and MMP-9 Expression in the Mouse Colon

Menglu Chen,¹,² Lei Gao,¹ Pan Chen,¹ Dandan Feng,¹ Yalin Jiang,¹ Yongchao Chang,² Jianjun Jin,¹ Fong-Fong Chu,¹,³ and Qiang Gao¹,⁴

¹Department of Gastroenterology and Hepatology, The First Affiliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, China
²Department of Clinical Laboratory, The First Affiliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, China
³Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA
⁴Department of Gastroenterology and Hepatology, Beijing Rehabilitation Hospital of Capital Medical University, 1 Gongliao Road, Shijingshan District, Beijing 100114, China

Correspondence should be addressed to Qiang Gao; gaoq@mail.haust.edu.cn

Received 3 March 2016; Revised 24 April 2016; Accepted 29 May 2016

Academic Editor: Mirella Giovarelli

Copyright © 2016 Menglu Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. 5-HT enhances dextran sulfate sodium- (DSS-) induced colitis and is involved in inflammatory bowel disease (IBD). Matrix metalloproteinases (MMPs) play roles in the process of intestinal inflammation. Aims. To examine whether 5-HT induces MMP expression in mouse colon to enhance DSS-induced colitis. Materials and Methods. C57BL/6J (B6) mice were treated with either low-dose (1.0 mg/kg) or high-dose (2.0 mg/kg) 5-HT by enema, low-dose (1.0%) or high-dose (2.5%) DSS, or combined low-dose (1.0%) DSS and (1.0 mg/kg) 5-HT. Mouse colitis was analyzed. MMPs and tissue inhibitors of MMPs (TIMPs) mRNA were measured by real-time quantitative RT-PCR in mouse colon and in human Caco-2 cells and neutrophils. MMP-3 and MMP-9 protein levels were quantified from immunohistochemistry (IHC) images of mouse colons. Results. 5-HT exacerbated DSS-induced colitis, low-dose 5-HT induces both MMP-3 and MMP-9, and high-dose 5-HT only increased MMP-3 mRNA expression in mouse colon. Mouse colon MMP-3 and MMP-9 protein levels were also elevated by 5-HT treatment. The MMP-2, TIMP-1, and TIMP-2 mRNA levels were increased in the inflamed colon. 5-HT induced MMP-3 and MMP-9 mRNA expression in Caco-2 and human neutrophils, respectively, in vitro. Conclusion. 5-HT induced MMP-3 and MMP-9 expression in mouse colon; these elevated MMPs may contribute to DSS-induced colitis.

1. Introduction

The inflammatory bowel disease (IBD), comprised of ulcerative colitis (UC) and Crohn's disease (CD), is the recurrent chronic idiopathic inflammatory disease of the GI tract [1–3]. Although the precise etiology of IBD remains unknown, a variety of inflammatory mediators and enzymes, such as cytokines, growth factors, reactive oxygen species (ROS), GI hormones, and matrix metalloproteinases (MMPs), are known to regulate inflammation and are involved in pathogenesis of IBD [4, 5].

5-Hydroxytryptamine (5-HT, serotonin), a monoamine neurotransmitter, is biochemically derived from tryptophan. Tryptophan hydroxylase (TPH) is a rate-limiting enzyme in the synthesis of 5-HT and is located prominently in enterochromaffin (EC) cells [6]. Approximately 90% of 5-HT in humans is synthesized in gastrointestinal (GI) EC cells by tryptophan hydroxylase-1 (TPH1) [7], and 5% of 5-HT is synthesized in myenteric neurons [8] and brain by TPH2 [9]. 5-HT is an important mucosal regulatory molecule, which mediates gut motility and secretory functions, promotes growth and turnover of mucosal epithelium,
and maintains intestinal homeostasis [10]. 5-HT is also a neurotransmitter in the central nervous system to regulate mood and cause vasoconstriction [10, 11]. In the intestinal mucosa, the serotonin reuptake transporter (SERT) takes up 5-HT into epithelial cells and serotonergic neurons and inactivates it [12]. 5-HT exerts its functions by binding to 5-HT receptors which are widely expressed in intestinal tissues [13, 14]. 5-HT is involved in the pathogenesis of intestinal disorders, including IBD [15–17] and irritable bowel syndrome [15, 18, 19]. The immunomodulatory effects of 5-HT are associated with gut inflammation [11]. The changes in EC cell numbers and 5-HT contents in colon mucosa of IBD patients have been reported [15, 20]. Mice treated with dextran sulfate sodium (DSS) to induce colitis also have increased 5-HT levels contributed by higher number of EC cells and decreased SERT mRNA expression [21]. 5-HT also exacerbated trinitrobenzene sulfonic acid- (TNBS-) induced mouse colitis and is believed to play a key role in pathogenesis of experimental colitis [22, 23].

MMPs are a class of structurally related zinc- and calcium-dependent enzymes, which are responsible for the metabolism of extracellular matrix (ECM) via the remodeling degradation of most components of the ECM [24, 25]. To date, 23 distinct MMPs have been identified in humans (24 in mice) [26]. MMPs facilitate cell migration and cell infiltration through degradation of basement membrane and ECM [24, 27]. MMPs catalyze proteolytic cleavage of biologically active protein molecules, such as cytokines, growth factors, and chemokines, from a membrane-anchored inactive form into a free active form to maintain tissue homeostasis. Under physiological conditions, MMPs are secreted as a latent form of enzyme at low levels and are converted to active enzymes by proteolytic cleavage [28]. The MMP proteins are tightly controlled at multiple levels, including transcription, translation, secretion, and activation [25, 26]. Additionally, MMP proteins are also regulated by tissue inhibitors of MMPs (TIMPs), which are endogenous inhibitors of MMPs. TIMPs consist of four members, TIMP-1, TIMP-2, TIMP-3, and TIMP-4, all of which regulate MMP activities by forming a 1:1 complex with the high zinc binding site of MMPs. TIMPs are important regulators of tissue remodeling and cellular behavior [29, 30].

In active IBD, many MMPs and TIMPs, including MMP-2, MMP-3, and MMP-9 and TIMP-1 and TIMP-2 were elevated in the flamed tissues compared to the noninflamed tissue [31–33]. MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are able to proteolytically degrade gelatin. Under physiological condition MMP-2 is ubiquitously expressed [26]. MMP-2 appears to be protective against DSS-, TNBS-, and Salmonella typhimurium-induced colitis [34]. MMP-9 is mainly secreted from inflammatory cells, such as neutrophils, monocytes, and macrophages and specially degrades basement membrane type IV collagen, as well as other ECM components [27, 35]. Of the MMPs, MMP-9 is the most abundantly expressed in inflamed tissues of IBD patients [33]. MMP-3 (stromelysin-1) is secreted by epithelial cells, fibroblasts, vascular smooth cells, endothelial cells, and macrophages [26, 36–39]. MMP-3 degrades ECM components such as fibronectin, denaturated collagens (gelatin), laminin, and proteoglycans [26]. Both MMP-3 and MMP-9 are believed to be involved in the process of IBD pathology [40, 41]. Proinflammatory cytokines, such as IL-6, IL-8, and TNF-α, can induce the transcription, translation, and secretion of MMPs [32, 42, 43].

DSS-induced colitis is an animal colitis model resembling ulcerative colitis. Although the mechanism by which DSS induces colitis is not clear, DSS damaged colon epithelium is highly relevant to human colitis [44]. It has been shown that DSS increases MMP-2, MMP-3, and MMP-9 mRNA levels in colon [45, 46]. In this study, we explored whether 5-HT exacerbated DSS-induced colitis can be contributed by MMPs expression in the colon.

2. Material and Methods

2.1. Animal Studies. C57BL/6J (B6) mice purchased from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China) were maintained in ventilated cages with free access to food and water. Mice were fed with rodent chow from Beijing HFK Bioscience Co. Ltd. (Beijing, China). Animal Care and Use Committee in the hospital approved all procedures in this study.

Male mice, at 6–8 weeks of age, with body weight of 20–25 g, were divided into 6 groups treated with 5-HT (MW 212.68, Sigma, St. Louis, USA, Cat. number H9523) or DSS (MW 36–50 kDa, MP Biomedicals, Santa Ana, USA, Cat. number 160110). These are (i) low-dose (1.0 mg/kg) 5-HT (n = 9) and (ii) high-dose (2.0 mg/kg) 5-HT (n = 9), both groups receiving 5-HT in saline by enema at days 1 and 4 [22]; (iii) low-dose (1%) DSS (n = 14) and (iv) high-dose (2.5%) DSS (n = 7), both groups receiving DSS in drinking water for 5 days; (v) DSS + 5-HT (n = 12), mice being treated with 1.0% DSS and 1 mg/kg 5-HT concurrently; (vi) control group (n = 8), mice receiving enema with saline. Mice were monitored daily for body weight and signs of colitis, including diarrhea and perianal ulceration to obtain disease activity index (DAI). Mice were euthanized at day six.

After euthanasia, the colon length was measured, and the sera were collected. The colon tissue was washed in PBS, and then half was fixed in 10% formalin and embedded in paraffin. Sections were stained by hematoxylin and eosin (H&E) for pathological examination or by immunohistochemistry (IHC). The other half of colon was stored at −80°C for RNA extraction. RNA later (Qiagen, Hilden, Germany) was used immediately when the samples were collected to prevent RNA degradation. The severity of colitis was evaluated by microscopic examination of colon tissues. Each mouse was scored for inflammation and pathology in a blinded fashion using a modified system as we described previously [47]. These include lymphocytes and neutrophil infiltration (0–3 points), Paneth cell and goblet cell degranulation (0–2 points), epithelium reactivity such as crypt distortion (0–3 points), and inflammatory foci (0–3 points). The threshold for detection of severe acute inflammation corresponds to scores of 6 in this study.

2.2. Immunohistochemical (IHC) Staining. Four-micron sections of paraffin-embedded samples were mounted on poly-L-lysine-coated slides. IHC was performed using a modified
Table 1: Primers sequence for qPCR.

| Species | mRNA     | Gene   | Primer sequence               | Amplicon (bp) |
|---------|----------|--------|-------------------------------|---------------|
| M       | NM-031168.1 | IL-6   | Forward 5'-AACGATGATGCACCTTGCAAGA  | 128           |
|         |          |        | Reverse 5'-GGTCTCCAGAAGACAGAGG |               |
| M       | NM-011339.2 | IL-8   | Forward 5'-CTAGGCACTTCGGTCGCTTCC | 217           |
|         |          |        | Reverse 5'-GGTCTCCAGAAGACAGAGG |               |
| M       | NM-013693.3 | TNF-α  | Forward 5'-CCACACAGCTCTTCTGTCTACT | 161           |
|         |          |        | Reverse 5'-GGTCTCCAGAAGACAGAGG |               |
| M       | NM-008610 | MMP-2  | Forward 5'-ACAGGTGTCGCTGTAAGT | 189           |
|         |          |        | Reverse 5'-AGGATGATGCTGTAAGT |               |
| M       | NM-010809.1 | MMP-3 | Forward 5'-ACACACACCGGCTTAT | 210           |
|         |          |        | Reverse 5'-ACACACACCGGCTTAT |               |
| M       | NM-013599 | MMP-9  | Forward 5'-CCGACATTTTGTGTCTTCC | 80            |
|         |          |        | Reverse 5'-GCACTGTCCTGCTGCA |               |
| M       | NM-001044384 | TIMP-1 | Forward 5'-TGGTCTGATGTGATGTG | 189           |
|         |          |        | Reverse 5'-TGGTCTGATGTGATGTG |               |
| M       | NM-011594 | TIMP-2 | Forward 5'-TGCAAGATGATGCTGTC | 102           |
|         |          |        | Reverse 5'-GACTGATGATGCTGTC |               |
| M       | NM-007393 | β-Actin| Forward 5'-CACGTCTGCGCTGCTG | 154           |
|         |          |        | Reverse 5'-CACGTCTGCGCTGCTG |               |
| H       | NM-002422.3 | MMP-3 | Forward 5'-ACACACACCGGCTTAT | 174           |
|         |          |        | Reverse 5'-ACACACACCGGCTTAT |               |
| H       | NM-004994.2 | MMP-9 | Forward 5'-TGGTCTGACCTGCTGCT | 244           |
|         |          |        | Reverse 5'-TGGTCTGACCTGCTGCT |               |
| H       | NM-001101 | β-Actin| Forward 5'-AGCAGTGTGTCGCTGACAG | 116       |
|         |          |        | Reverse 5'-AGCAGTGTGTCGCTGACAG |               |

M: mouse, H: human.

2.3. Quantitative Real-Time PCR (qPCR). qPCR was performed as described previously [31]. Briefly, total RNA was extracted using TRIzol Reagent (Invitrogen, USA) according to the manufacturer’s instruction. The cDNA was synthesized using PrimeScript™ RT Master Mix (Takara, Japan). The primer sequences for human and mouse samples (Table 1) were designed with Primer3.0 [48] and the primers were synthesized by Sangon Biotechnology (Zhengzhou, China). The reaction mixture of real-time qPCR was performed using a CFX96™ Real-Time PCR system (BIO-RAD, USA), and the cyber green was used to detect PCR products. When the primers annealing temperature was 60°C or more, a two-step PCR reaction method was used. When the primers annealing temperature was below 60°C, a three-step method was used. Each sample was assayed in triplicate. The efficiency of PCR amplification was 97% to 105%. A melting curve analysis was performed for the PCR products of each target gene and β-actin to evaluate primer specificity. The relative abundance of target gene mRNA level was evaluated using the comparative Ct ($2^{-ΔΔCt}$) method and was normalized to β-actin mRNA level. The mRNA expression level was presented by the relative fold by comparing the quantity of mRNA in different groups. When the Ct value is higher than 35, the gene is considered as unexpressed.

2.4. Cell Culture. Caco-2, a human colon enterocyte-like cell line (ATCC), was cultured at 37°C in an atmosphere of 5% CO2 and maintained in high-glucose DMEM supplemented with 2 mM glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 1% nonessential amino acids, and 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Utah, USA).
For 5-HT stimulation experiments, cells were seeded in 12-well plates at a density of 1.25 × 10⁵ cells/well. The cells were serum-starved for 24 h before adding 5-HT to minimize the effect of 5-HT present in the FBS. 5-HT was added to the serum-free medium at different concentrations for up to 24 h.

Heparinized blood samples were collected from consented healthy volunteers. The blood samples were seeded in 6-well plates at a volume of 1.5 mL/well of DMEM and were stimulated with 5-HT for 24 h. Leucocytes were isolated from the wells by the addition of erythrocyte lysis buffer, containing 0.16 M NH₄Cl, 10 mM KHCO₃, and 0.01 mM K₂·EDTA (pH 7.4) at 4°C. The lysate was transferred into a 15 mL centrifuge tube and centrifuged at 1500 rpm, 4°C for 5 min to pellet leucocytes, which were immediately processed for RNA isolation and determination of MMP-9 mRNA levels.

2.5. Statistical Analysis. Student’s t-test, one-way analysis of variance (ANOVA), and Mann-Whitney U test were used to compare the data from different groups. The significant difference was defined as P < 0.05. Data was reported as means ± standard deviations (SD). All statistical analysis was performed by using the SPSS 19.0 statistics package (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. 5-HT Exaggerated DSS-Induced Colitis. Similar to Regmi’s study that 5-HT exaggerated TNBS-induced colitis [22] (Table 2, Figures 1 and 2), 5-HT alone, at either low (1.0 mg/kg) or high (2.0 mg/kg) dosage, did not induce colitis determined by DAI and histopathological analysis. Mice treated with 1% DSS had signs of mild colitis, including diarrhea and loss of body weight shown at day 5, but the weight loss was less than 10% at day 6. Mild inflammation was seen in colon tissue sections, including increased infiltration of inflammatory cells in the mucosa and submucosa, mild crypt distortion, and shortened crypt depth. Mice drinking 2.5% DSS suffered severe colitis, diarrhea, bloody stools, and losing 21% of body weight at day 5. Mice receiving both 1% DSS and 1 mg/kg 5-HT had a similar extent of colitis as those receiving high-dose DSS. The shortened colon was associated with the increased DAI. The pathological analysis demonstrated severe inflammation, including ulcerative lesions, increased number of infiltrating inflammatory cells, crypt loss, and erosion of the mucosa and submucosa.

While 5-HT alone did not induce colitis, high-dose 5-HT significantly increased the levels of proinflammatory cytokine IL-6 and chemokine IL-8 mRNA in the colons (Table 3). DSS alone strongly induced IL-6 mRNA and TNF-α, but not IL-8 mRNA levels. Combined 1% DSS and 1 mg/kg 5-HT treatment produced the same pattern of cytokine/chemokine expression as the DSS treatment, that is, no induction of IL-8 mRNA levels.

3.2. 5-HT Increased MMP-3 and MMP-9, but Not MPP-2, TIMP-1, and TIMP-2, mRNA Levels in Mouse Colon. MMPs play an important role in tissue modeling and damage in IBD [31, 41], and the proteolytic activity of MMPs is tightly regulated by their natural inhibitors, TIMPs [29, 30]; we explored whether MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 mRNA expressions are induced by 5-HT in mouse colons. We found that 5-HT alone increased both MMP-3 and MMP-9 mRNA levels; low-dose and high-dose 5-HT increased MMP-3 mRNA by 2- and 4-fold, respectively (Figure 3). Low-dose 5-HT also induced MMP-9 mRNA by 5.5-fold, although high-dose 5-HT did not increase MMP-9

| Group               | Control | 1 mg 5-HT | 2 mg 5-HT | 1% DSS | 1% DSS + 1 mg 5-HT | 2.5% DSS |
|---------------------|---------|-----------|-----------|--------|------------------|---------|
| n                   | 8       | 9         | 9         | 14     | 12               | 7       |
| Change of BW (%)†  | 2.1 ± 2.4 | 1.8 ± 1.8 | 0.9 ± 3.3 | −5.9 ± 4.2* | −19.0 ± 5.9* | −21.6 ± 5.9* |
| Colon length (cm)   | 7.8 ± 0.5 | 7.6 ± 0.3 | 7.4 ± 0.4 | 6.4 ± 0.6* | 5.2 ± 0.7* | 4.9 ± 0.5* |
| Colon H&E staining  | 0.1 ± 0.1 | 0.3 ± 0.1 | 0.4 ± 0.2 | 6.3 ± 0.9* | 10.7 ± 2.5* | 11.6 ± 1.9* |

† Change of BW presents the change of mouse body weight at day 6.

* P < 0.05 versus control mice.
mRNA levels significantly. Contrary to MMP-3 and MMP-9 mRNA expressions, 5-HT alone did not affect MMP-2, TIMP-1, and TIMP-2 mRNA expression.

Consistent with the literature, DSS-treated colons had elevated expression of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 mRNAs with the exception of TIMP-2 mRNA in low-dose DSS-treated colon (Table 4). Induction of MMP-2 and TIMP-2 by DSS and DSS + 5-HT was rather modest; MMP-2 was increased 1.8- to 6.3-fold and TIMP-2 was increased 3.8- to 6.0-fold. Induction of MMP-3, MMP-9, and TIMP-1 reached 2-log higher in mice treated with either DSS + 5-HT or high-dose DSS compared with the control mice.

### Table 3: 5-HT increases cytokine gene expression in mouse colon.

| Group                  | Control | 1 mg 5-HT | 2 mg 5-HT | 1% DSS | 1% DSS + 1 mg 5-HT | 2.5% DSS |
|------------------------|---------|-----------|-----------|--------|-------------------|----------|
| n                      | 8       | 9         | 9         | 14     | 12                | 7        |
| IL-6                   | 1 ± 0.1 | 1.4 ± 0.3 | 2.6 ± 0.6* | 144 ± 24.2* | 1722 ± 415.9* | 1070 ± 445.1* |
| IL-8                   | 1 ± 0.4 | 1.3 ± 0.3 | 3.7 ± 0.6* | 0.9 ± 0.1 | 1.8 ± 0.05 | 1.1 ± 0.1 |
| TNF-α                  | 1 ± 0.2 | 1.5 ± 0.1 | 1.7 ± 0.3 | 5.6 ± 0.8* | 8.5 ± 1.6* | 9.8 ± 1.2* |

* P < 0.05 versus control mice.
§ The data stands for relative fold of cytokine mRNA.

### 3.3. 5-HT Increased MMP-3 and MMP-9 Protein Levels in Mouse Colon Analyzed by IHC

We performed MMP-3 IHC and found that MMP-3 was located at epithelial cells, endothelial cells, and some infiltrating cells in the lamina propria (Figure 4, top panels). We quantified the protein levels based on the number of positively stained cells in the field. Consistent with gene expression, the MMP-3 protein levels were elevated 3.7-fold in the colons of mice treated with high-dose 5-HT, although the smaller increase

---

**Figure 2:** Histopathological analysis of mouse colon treated with 5-HT or DSS. There was no colitis in control group (n = 8) or alone receiving 1.0 mg/kg (n = 9) or 2.0 mg/kg 5-HT (n = 9). Mild colitis was in mice treated with 1.0% DSS (n = 14). Both mice receiving 1.0% DSS plus 1.0 mg/kg 5-HT (n = 12) and 2.5% DSS (n = 7) had significant severe colitis, demonstrating the increased number of infiltrating inflammatory cells, crypt loss, and erosion of the mucosa and submucosa.

**Figure 3:** 5-HT alone increased MMP-3 and MMP-9 mRNA expressions in mouse colon. The treatment with low-dose 5-HT increased MMP-9 mRNA expression in mouse colon tissues; high dose only increased MMP-3 mRNA. Neither low- nor high-dose 5-HT increased the expression of MMP-2, TIMP-1, or TIMP-2 mRNA. Results are expressed as the mean ± standard deviations (SD) and 8 mice were included for all three groups. Multiple comparisons among group were done. *P < 0.05 versus control mice. †P < 0.05 versus 1 mg 5-HT group.
### Table 4: Analysis of MMPs mRNA in mouse colon.

| Group       | Control         | 1% DSS          | 1% DSS + 1 mg 5-HT | 2.5% DSS       |
|-------------|-----------------|-----------------|--------------------|----------------|
| MMP-2       | 1.0 ± 0.04      | 1.8 ± 0.2∗      | 2.9 ± 0.2∗         | 6.3 ± 0.3∗     |
| MMP-3       | 1.0 ± 0.05      | 28.1 ± 12.2∗    | 218 ± 101.5∗       | 170 ± 37∗      |
| MMP-9       | 1.0 ± 0.06      | 11.8 ± 2.0∗     | 52.7 ± 9.6∗        | 111.4 ± 19.8∗  |
| TIMP-1      | 1.0 ± 0.03      | 9.8 ± 3.5∗      | 114.6 ± 27.3∗      | 82.1 ± 10.7∗   |
| TIMP-2      | 1.0 ± 0.03      | 1.2 ± 0.2       | 6.0 ± 1.9∗         | 3.8 ± 0.5∗     |

* P < 0.05 versus control mice.
The data presents 8 mice of each group and stands for relative fold.

![MMP-3 and MMP-9 IHC staining](image)

**Figure 4**: IHC staining of MMP-3 and MMP-9 in mouse colon tissue. The low expression MMP-3 was in colon tissue of control mice. The expression of MMP-3 was increased in the colon tissue of mice treated with high-dose 5-HT, further increased in severe inflammatory tissue. MMP-3 mainly located in infiltrating cells and stromal cells, some epithelial cell having weak staining. MMP-9 was increased in low 5-HT group but not in high-dose group and also highly increased in tissue with severe inflammation. MMP-9 was located mainly in inflammatory cells. Six mice from each group were included for IHC staining.

3.4. 5-HT Increases MMP-3 in Caco-2 Cells and MMP-9 mRNA in Leucocytes. Since MMP-3 is expression in colon epithelial cells and MMP-9 is mainly synthesized in leukocytes [26, 35], we tested the direct effect of 5-HT on the expression MMP-3 in Caco-2 cells and MMP-9 mRNA in leukocytes. In Caco-2 cells, 5-HT significantly increased the MMP-3 mRNA levels after 24 h treatment with either 5 or 10 μM 5-HT compared to the control cells (Figure 5(a)). MMP-9 mRNA level was not changed under the same conditions (data not shown). MMP-9 mRNA level in leukocytes was also increased 6-fold after 24 h treatment with 10 μM 5-HT (Figure 5(b)). No MMP-3 mRNA was detected in leukocytes (data not shown).

4. Discussion

5-HT is involved in pathogenesis of IBD [15–17] and is well documented to exacerbate chemical-induced colitis in mice [22, 23]. The development of IBD is associated with changes of EC cells [49, 50]. The elevated EC cell number and decreased SERT mRNA expression lead to increase in 5-HT content, which is associated with the pathogenesis of DSS-induced colitis [21]. Since MMPs are upregulated in IBD and other inflammatory conditions and DSS treatment induced MMP-2, MMP-3, and MMP-9 mRNA levels in mouse colon [45, 46], we analyzed the direct effect of 5-HT on the expression of these MMP genes. We found 5-HT alone induced MMP-3 and MMP-9 but not MMP-2 gene expression in the colon. Furthermore, we showed the direct effect of 5-HT induction of MMP-3 expression in Caco-2 cells and MMP-9 expression in leucocytes. Thus, we provided the first evidence to show that 5-HT has a direct effect on the induction of MMPs in two different cell types.

5-HT-induced MMP-3 and MMP-9 gene expression may be mediated by induction of proinflammatory cytokines, since IL-6 and IL-8 mRNA levels are significantly elevated in the colons of mice treated with high-dose 5-HT. Induction
Table 5: Analysis of MMP-3 and MMP-9 protein levels by IHC in mouse colon.

| Group       | n   | Control | 1 mg 5-HT | 2 mg 5-HT | 1% DSS | 1% DSS + 1 mg 5-HT | 2.5% DSS |
|-------------|-----|---------|-----------|-----------|--------|-------------------|---------|
| MMP-3       | 6   | 0.5 ± 0.5 | 0.8 ± 1.0 | 3.7 ± 0.8<sup>§</sup> | 5.7 ± 2.0<sup>§</sup> | 8.8 ± 2.0<sup>§</sup> | 8.2 ± 3.8<sup>§</sup> |
| MMP-9       | 6   | 0.3 ± 0.5 | 3.0 ± 1.1<sup>§</sup> | 0.7 ± 0.8 | 4.2 ± 1.0<sup>§</sup> | 9.0 ± 2.7<sup>§</sup> | 7.5 ± 4.2<sup>§</sup> |

* P < 0.05 versus control mice; § P < 0.05 versus 1 mg 5-HT group for MMP-3 or versus 2 mg 5-HT group for MMP-9.

Figure 5: The expression of MMP-3 and MMP-9 mRNA in Caco-2 cells and human leucocytes. After 24 h stimulation with 5-HT for 24 h, MMP-3 mRNA expression in Caco-2 cells was significantly increased at the concentration of 5 and 10 μM (a). The expression of MMP-9 mRNA was up to 6-fold increase compared to the leucocytes without 5-TH stimulation (b). The data represent 4 experiments. * P < 0.05 versus cells without treatment with 5-HT.

of the same proinflammatory cytokines is in rat colons after being treated by 1.0 mg/kg 5-HT [22]. These 5-HT activated cytokines and chemokine are produced by local neutrophils, monocytes/macrophages, dendritic cells, and T cells [51–53] and are known to induce MMP-3 expression [37, 38]. MMP-9 is predominantly synthesized in inflammatory cells, and the consequence of MMP-9 induction draws more leukocytes from the circulation to colon mucosa to worsen inflammation [54]. Furthermore, MMP-9 can potentiate IL-8 activity tenfold, further enhancing the chemokine activity [55]. Therefore, mice treated with combined 5-HT and low-dose DSS could produce as severe colitis as mice treated with high-dose DSS.

We noted that the expression of MMP-9 in gene and protein was no longer increased in the colons of mice treated with high-dose 5-HT in spite of having high levels of IL-6, IL-8, and TNF-α expression. It suggested that there is a dose-effect of 5-HT on MMP-9 expression. Apparently there is a negative feedback mechanism between MMP-9 protein and 5-HT biosynthesis, since in Mmp9<sup>−/−</sup> mice, the TPH1 gene expression is highly regulated [56]. Therefore, the high level of 5-HT inhibits further induction of MMP-9 gene, although the exact mechanism is unknown.

While MMP-2 has the same function with that of MMP-9 in proteolytical degradation of gelatin, the expression of MMP-2 is ubiquitous and constitutive under physiological conditions [25, 26]. The expression of MMP-2 does not respond to inflammatory stimuli because MMP-2 gene lacks the binding site for inflammatory transcription factor [26]. It is possible that the high basal level of MMP-2 expression makes it more difficult to detect a low level of induction by 5-HT. This point is supported by the smaller fold of induction in DSS-treated colons; MMP-2 gene was induced 1.8- to 6.3-fold, whereas MMP-3 was induced 28- to 218-fold, and MMP-9 was 11- to 111-fold. Although we did not test the function of MMPs analyzed in this study, we suspect the elevated expression of MMP-9 aids, while MMP-2 suppresses inflammation as illustrated by several groups [57, 58]. The function of MMP-3 is less clear in the colon.

5-HT did not affect TIMP-1 and TIMP-2 gene expression, although DSS-induced strong inflammation induced both TIMP gene expressions. The similar pattern of induction of TIMPs and MMPs has been reported for IBD patients [59]. It was reported that the ratio of MMP-3/TIMP-1 is increased in inflamed colons compared with noninflamed colon tissues of IBD patients [60]. The results from human and animal model indicate that MMPs and TIMPs are involved in the process of inflammation and their expressions are regulated by multifactor and multistep, and cytokines and growth factors are involved in expression regulation of both MMPs and TIMPs [30, 61].

Judging from the higher fold of induction for TIMP-1 (10- to 115-fold) than TIMP-2 (3.8- to 6.0-fold) and the fold of induction of MMP-2 and MMP-9, it is consistent with the notion that MMP-2 is primarily inhibited by TIMP-2 while MMP-9 is mainly inhibited by TIMP-1 [62, 63]. In IBD patients after the remission of intestinal inflammation by Infliximab, a chimeric monoclonal anti-TNF-α antibody, the upregulated MMPs and TIMPs, including MMP-2, MMP-3, and MMP-9 and TIMP-1 and TIMP-2, were recessed [59].
Besides inhibition of MMPs, TIMPs have many other functions such as regulation of cell proliferation, cell migration, angiogenesis, and apoptosis [29].

5. Conclusion

Our findings show that 5-HT induces the expression of MMP-3 and MMP-9 in mouse colon. This is a direct effect since 5-HT induces MMP-3 mRNA levels in human colon cancer Caco-2 cells and MMP-9 mRNA in human primary culture of leucocytes. Our results support the notion that 5-HT exacerbates DSS-induced colitis by enhancing the production of MMP-3 and MMP-9. The significance of our findings is that we have provided a link between 5-HT-associated colitis and MMPs.

Competing Interests

The authors declare that they have no conflict of interests.

Authors’ Contributions

Menglu Chen and Lei Gao are equal contributors to this study.

Acknowledgments

This study is supported by a Grant (no. 81370487 to Qiang Gao) from National Natural Science Foundation of China.

References

[1] A. Kaser, S. Zeissig, and R. S. Blumberg, “Inflammatory bowel disease,” Annual Review of Immunology, vol. 28, pp. 573–621, 2010.

[2] S. I. Grivennikov, “Inflammation and colorectal cancer: colitis-associated neoplasia,” Seminars in Immunopathology, vol. 35, no. 2, pp. 229–244, 2013.

[3] J. Terzić, S. Grivennikov, E. Karin, and M. Karin, “Inflammation and colon cancer,” Gastroenterology, vol. 138, no. 6, pp. 2101–2114.e5, 2010.

[4] K. L. Wallace, L.-B. Zheng, Y. Kanazawa, and D. Q. Shih, “Immunopathology of inflammatory bowel disease,” World Journal of Gastroenterology, vol. 20, no. 1, pp. 6–21, 2014.

[5] Y.-Z. Zhang and Y.-Y. Li, “Inflammatory bowel disease: pathogenesis,” World Journal of Gastroenterology, vol. 20, no. 1, pp. 91–99, 2014.

[6] D. J. Walthier and M. Bader, “A unique central tryptophan hydroxylase isoform,” Biochemical Pharmacology, vol. 66, no. 9, pp. 1673–1680, 2003.

[7] G. Bertaccini, “Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat,” The Journal of Physiology, vol. 153, no. 2, pp. 239–249, 1960.

[8] M. D. Gershon, A. B. Drakontides, and L. L. Ross, “Serotonin: synthesis and release from the myenteric plexus of the mouse intestine,” Science, vol. 149, no. 3680, pp. 197–199, 1965.

[9] P. M. Whitaker-Azmitia, “The discovery of serotonin and its role in neuroscience,” Neuropsychopharmacology, vol. 21, supplement 2, pp. 2S–8S, 1999.

[10] G. M. Mawe and J. M. Hoffman, “Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets,” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 8, pp. 473–486, 2013.

[11] R. Arreola, E. Becerril-Villanueva, C. Cruz-Fuentes et al., “Immunomodulatory effects mediated by serotonin,” Journal of Immunology Research, vol. 2015, Article ID 354957, 21 pages, 2015.

[12] P. R. Wade, J. Chen, B. Jaffe, I. S. Kassem, R. D. Blakely, and M. D. Gershon, “Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract,” The Journal of Neuroscience, vol. 16, no. 7, pp. 2352–2364, 1996.

[13] D. Hoyer, J. P. Hannon, and G. R. Martin, “Molecular, pharmacological and functional diversity of 5-HT receptors,” Pharmacology Biochemistry and Behavior, vol. 71, no. 4, pp. 533–554, 2002.

[14] J. Hannon and D. Hoyer, “Molecular biology of 5-HT receptors,” Behavioural Brain Research, vol. 195, no. 1, pp. 198–213, 2008.

[15] M. D. Coates, C. R. Mahoney, D. R. Linden et al., “Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome,” Gastroenterology, vol. 126, no. 7, pp. 1657–1664, 2004.

[16] I. M. Minderhoud, B. Oldenburg, M. E. I. Schipper, J. J. M. ter Linde, and M. Samsom, “Serotonin synthesis and uptake in symptomatic patients with Crohn’s disease in remission,” Clinical Gastroenterology and Hepatology, vol. 5, no. 6, pp. 714–720, 2007.

[17] I. I. Stoyanova and M. V. Gulubova, “Mast cells and inflammatory mediators in chronic ulcerative colitis,” Acta Histochemica, vol. 104, no. 2, pp. 183–192, 2002.

[18] C. P. Bearcroft, D. Perrett, and M. J. G. Farthing, “Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study,” Gut, vol. 42, no. 1, pp. 42–46, 1998.

[19] R. C. Spiller, D. Jenkins, J. P. Thornley et al., “Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome,” Gut, vol. 47, no. 6, pp. 804–811, 2000.

[20] M. El-Salhy, Å. Danielsson, R. Stenling, and L. Grimelius, “Colonic endocrine cells in inflammatory bowel disease,” Journal of Internal Medicine, vol. 242, no. 5, pp. 413–419, 1997.

[21] P. P. Bertrand, A. Barajas-Espinosa, S. Neshat, R. L. Bertrand, and A. E. Lomax, “Analysis of real-time serotonin (5-HT) availability during experimental colitis in mouse,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 298, no. 3, pp. G446–G455, 2010.

[22] S. C. Regmi, S.-Y. Park, S. K. Ku, and J.-A. Kim, “Serotonin regulates innate immune responses of colon epithelial cells through Nox2-derived reactive oxygen species,” Free Radical Biology and Medicine, vol. 69, pp. 377–389, 2014.

[23] J.-E. Ghia, N. Li, H. Wang et al., “Serotonin has a key role in pathogenesis of experimental colitis,” Gastroenterology, vol. 137, no. 5, pp. 1649–1660, 2009.

[24] R. Visse and H. Nagase, “Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry,” Circulation Research, vol. 92, no. 8, pp. 827–839, 2003.

[25] H. Nagase and J. F. Woessner Jr., “Matrix metalloproteinases,” The Journal of Biological Chemistry, vol. 274, no. 31, pp. 21491–21494, 1999.
Mediators of Inflammation

[26] T. Klein and R. Bischoff, "Physiology and pathophysiology of matrix metalloproteases," *Amino Acids*, vol. 41, no. 2, pp. 271–290, 2011.

[27] R. P. Iyer, N. L. Patterson, G. B. Fields, and M. L. Lindsey, "The history of matrix metalloproteases: milestones, myths, and misperceptions," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 303, no. 8, pp. H919–H930, 2012.

[28] S. S. Apte and W. C. Parks, "Metalloproteinases: a parade of functions in matrix biology and an outlook for the future," *Matrix Biology*, vol. 44–46, pp. 1–6, 2015.

[29] K. Brew and H. Nagase, "The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity," *Biochimica et Biophysica Acta (BBA)—Molecular Cell Research*, vol. 1803, no. 1, pp. 55–71, 2010.

[30] G. Murphy, "Tissue inhibitors of metalloproteinases," *Genome Biology*, vol. 12, no. 11, p. 233, 2011.

[31] Q. Gao, M. I. W. Meijer, F. J. G. M. Kuiken et al., "Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases," *Digestive and Liver Disease*, vol. 37, no. 8, pp. 584–592, 2005.

[32] C. Medina and M. W. Radomski, "Role of matrix metalloproteinases in intestinal inflammation," *Journal of Pharmacology and Experimental Therapeutics*, vol. 318, no. 3, pp. 933–938, 2006.

[33] M. D. Baugh, M. J. Perry, A. P. Hollander et al., "Matrix metalloproteinase levels are elevated in inflammatory bowel disease," *Gastroenterology*, vol. 117, no. 4, pp. 814–822, 1999.

[34] P. Garg, M. Vijay-Kumar, L. Wang, A. T. Gewirtz, D. Merlin, and S. V. Sitaraman, "Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis," *American Journal of Physiology—Gastrointestinal and Liver Physiology*, vol. 296, no. 2, pp. G175–G184, 2009.

[35] E. Hadler-Olsen, B. Fadnes, I. Sylte, L. Uhlin-Hansen, and J.-O. Winberg, "Regulation of matrix metalloproteinase activity in health and disease," *The FEBS Journal*, vol. 278, no. 1, pp. 28–45, 2011.

[36] K. Warstat, T. Pap, G. Klein, S. Gay, and W. K. Aicher, "Co-activation of synovial fibroblasts by laminin-111 and transforming growth factor-β induces expression of matrix metalloproteinases 3 and 10 independently of nuclear factor-κB," *Annals of the Rheumatic Diseases*, vol. 67, no. 4, pp. 559–562, 2008.

[37] H. Unoki, H. Bujo, M. Jiang, T. Kawamura, K. Murakami, and Y. Saito, "Macrophages regulate tumor necrosis factor-α expression in adipocytes through the secretion of matrix metalloproteinase-3," *International Journal of Obesity*, vol. 32, no. 6, pp. 902–911, 2008.

[38] R. Hanemaaijer, P. Koolwijk, L. Le Clercq, W. J. A. De Vree, and V. W. M. Van Hinsbergh, "Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumour necrosis factor-α, interleukin 1 and phorbol ester," *Biochemical Journal*, vol. 296, no. 3, pp. 803–809, 1993.

[39] R. Blindt, F. Vogt, D. Lamby et al., "Characterization of differential gene expression in quiescent and invasive human arterial smooth muscle cells," *Journal of Vascular Research*, vol. 39, no. 4, pp. 340–352, 2002.

[40] A. Kofla-Dlibacz, M. Matusiewicz, M. Krzystek-Korpacka, and B. Iwanca, "Correlation of MMP-3 and MMP-9 with croxin's disease activity in children," *Digestive Diseases and Sciences*, vol. 57, no. 3, pp. 706–712, 2012.

[41] S. O'Sullivan, J. F. Gilmer, and C. Medina, "Matrix metalloproteinases in inflammatory bowel disease: an update," *Mediators of Inflammation*, vol. 2015, Article ID 964131, 19 pages, 2015.

[42] P. Kothari, R. Pestana, R. Mesarova et al., "IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages," *Journal of Immunology*, vol. 192, no. 1, pp. 349–357, 2014.

[43] A. Li, S. Dubey, M. L. Varney, B. J. Dave, and R. K. Singh, "IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinase production and regulated angiogenesis," *The Journal of Immunology*, vol. 170, no. 6, pp. 3369–3376, 2003.

[44] B. Chassaing, J. D. Aitken, M. Malleshappa, and M. Vijay-Kumar, "Dextran sulfate sodium (DSS)-induced colitis in mice," *Current Protocols in Immunology*, vol. 104, Unit 15.25, 2014.

[45] D. K. Park and H.-J. Park, "Ethanol extract of Cordyceps militaris grown on germinated soybeans attenuates dextran-sodium-sulfate- (DSS-) induced colitis by suppressing the expression of matrix metalloproteinases and inflammatory mediators," *BioMed Research International*, vol. 2013, Article ID 102918, 10 pages, 2013.

[46] K. Suzuki, X. Sun, M. Nagata et al., "Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium," *Pathology International*, vol. 61, no. 4, pp. 228–238, 2011.

[47] F.-F. Chu, R. S. Esworthy, P. G. Chu et al., "Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes," *Cancer Research*, vol. 64, no. 3, pp. 962–968, 2004.

[48] A. Untergasser, I. Cutcutache, T. Koressaar et al., "Primer3-new capabilities and interfaces," *Nucleic Acids Research*, vol. 40, no. 15, article e115, 2012.

[49] A. E. Bishop, R. Pietroletti, C. W. Taat, W. H. Brummelkamp, and J. M. Polak, "Increased populations of endocrine cells in Crohn's ileitis," *Virchows Archiv A: Pathological Anatomy and Histopathology*, vol. 410, no. 5, pp. 391–396, 1987.

[50] A. A. Ahonen, K. Kyosola, and O. Penttilä, "Enterochromaffin cells and macrophages in ulcerative colitis and irritable colon," *Annals of Clinical Research*, vol. 8, no. 1, pp. 1–7, 1976.

[51] P. J. O'Connell, X. Wang, M. Leon-Ponte, C. Griffiths, S. C. Pingle, and G. P. Ahern, "A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells," *Blood*, vol. 107, no. 3, pp. 100–1017, 2006.

[52] T. Dürk, E. Panther, T. Müller et al., "5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes," *International Immunology*, vol. 17, no. 5, pp. 599–606, 2005.

[53] T. Müller, T. Dürk, B. Blumenthal et al., "5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo," *PLoS ONE*, vol. 4, no. 7, Article ID e6453, 2009.

[54] A. M. Manicone and J. K. McGuire, "Matrix metalloproteinases as modulators of inflammation," *Seminars in Cell and Developmental Biology*, vol. 19, no. 1, pp. 34–41, 2008.

[55] P. E. Van den Steen, P. Proost, A. Wuyts, J. Van Damme, and G. Opdenakker, "Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES and MCP-2 intact," *Blood*, vol. 96, no. 8, pp. 2673–2681, 2000.

[56] G. Christoffersson, T. Waldén, M. Sandberg, G. Opdenakker, P.-O. Carlsson, and M. Phillipson, "Matrix metalloproteinase-9 is essential for physiological beta cell function and islet dysfunction in non-obese diabetic mice," *Diabetes*, vol. 53, no. 4, pp. 932–941, 2004.
vascularization in adult mice,” *American Journal of Pathology*, vol. 185, no. 4, pp. 1094–1103, 2015.

[57] P. Garg, M. Rojas, A. Ravi et al., “Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis,” *Journal of Immunology*, vol. 177, no. 6, pp. 4103–4112, 2006.

[58] P. Nighot, R. Al-Sadi, M. Rawat, S. Guo, D. M. Watterson, and T. Ma, “Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis,” *American Journal of Physiology—Gastrointestinal and Liver Physiology*, vol. 309, no. 12, pp. G988–G997, 2015.

[59] M. de Bruyn, K. Machiels, J. Vandooren et al., “Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease,” *Inflammatory Bowel Diseases*, vol. 20, no. 2, pp. 339–352, 2014.

[60] B. Von Lampe, B. Barthel, E.-O. Riecken, S. E. Coupland, and S. Rosewicz, “Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease,” *Gut*, vol. 47, no. 1, pp. 63–73, 2000.

[61] I. M. Clark, T. E. Swingler, C. L. Sampieri, and D. R. Edwards, “The regulation of matrix metalloproteinases and their inhibitors,” *International Journal of Biochemistry and Cell Biology*, vol. 40, no. 6-7, pp. 1362–1378, 2008.

[62] S. J. Crocker, A. Pagenstecher, and I. L. Campbell, “The TIMPs tango with MMPs and more in the central nervous system,” *Journal of Neuroscience Research*, vol. 75, no. 1, pp. 1–11, 2004.

[63] P. Devarajan, J. J. Johnston, S. S. Ginsberg, H. E. Van Wart, and N. Berliner, “Structure and expression of neutrophil gelatinase cDNA: identity with type IV collagenase from HT1080 cells,” *Journal of Biological Chemistry*, vol. 267, no. 35, pp. 25228–25232, 1992.